Thermo Fisher Scientific Inc
TMO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$742.00 | Rlbsx | Zvvzvsjjs |
Thermo Fisher Scientific Raises Guidance on Strong Pandemic Revenue
Thermo Fisher delivered strong results in the third quarter, with the delta variant surge propelling demand for testing across the globe. Pandemic response revenue of $2 billion in the quarter was above our estimates, and we anticipate raising our revenue projections for 2021 to match the company's adjusted guidance. Impressively, the firm also raised its 2022 revenue guidance on the strength of its core business. We expect a small upward adjustment to our fair value estimate but continue to view shares as overvalued. Thermo Fisher's wide moat rating is intact.